Helix BioPharma Corp. Reports Voting Results and Appointment of New Board Director
RICHMOND HILL, ON / ACCESSWIRE / January 28, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the voting …
RICHMOND HILL, ON / ACCESSWIRE / January 28, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the voting results of the Company's annual and special meeting of shareholders held on January 28, 2022 (the "Meeting"). In aaccordance with section11.3 of National Instrument 51-102 Continuous Disclosure Obligations, and the appointment of Mr. Adam Uszpolewicz to Helix's Board of Directors.
"We are very excited to have Mr. Uszpolewicz join the Company's Board of Directors", said Prof Slawomir Majewski. Mr. Uszpolewicz brings 30 years of professional experience working in varied financial services sectors, including life, health and general insurance, asset management, pensions, banking and management consulting, and has significant experience leading M&A transactions.
There were 23 shareholders represented in person or by proxy at the Meeting holding 53,429,429 common shares, representing approximately 37.5% of Helix's total issued and outstanding shares. Below is a summary of the resultsof matters voted on at the Meeting.
1. Election of Directors
Lesen Sie auch
Each of the nominees for election as directors listed in Helix's management information circular dated December 17, 2021 was elected as a director of Helix for the ensuing year or until their successors are elected or appointed. Management received proxies in respect of the election of directors of Helix as follows:
Votes For |
Votes Withheld |
|||
# |
% |
# |
% |
|
Slawomir Majewski |
52,916,642 |
99.9% |
911 |
0.1% |
Artur Gabor |
52,917,442 |
99.9% |
111 |